bexarotene has been researched along with Local Neoplasm Recurrence in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elsea, D; Lilley, C; Lisano, J; Liu, J; Savage, KJ; Yu, KS | 1 |
| Assaf, C; Nicolay, JP | 1 |
| Duvic, M; Gangar, P; Talpur, R; Thompson, A | 1 |
| Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
| Catherwood, M; Morris, TC; Pettengell, R; Sheehy, O | 1 |
| Amitay-Laish, I; David, M; Hodak, E | 1 |
| Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S | 1 |
| Alves, R; Fernandes, I; Lima, M; Oliveira, A; Selores, M | 1 |
| Chu, J; Marmon, S; Meehan, S; Patel, R; Pomeranz, MK | 1 |
| Crowley, CA; Heald, P; Martin, AG; Mehlmauer, M; Reich, SD; Yocum, RC | 1 |
2 review(s) available for bexarotene and Local Neoplasm Recurrence
| Article | Year |
|---|---|
[Treatment of mycosis fungoides and Sézary syndrome].
Topics: Adrenal Cortex Hormones; Bexarotene; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immunoconjugates; Interferon-alpha; Mycosis Fungoides; Neoplasm Recurrence, Local; Neoplasm Staging; Phototherapy; Polyethylene Glycols; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; World Health Organization | 2017 |
Recurrent localized primary cutaneous marginal-zone B cell lymphoma.
Topics: Adult; Antigens, CD20; Arm; Bexarotene; Biomarkers, Tumor; Biopsy; Combined Modality Therapy; Humans; Ki-67 Antigen; Lymphoma, B-Cell, Marginal Zone; Male; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Skin Neoplasms; Tetrahydronaphthalenes | 2011 |
2 trial(s) available for bexarotene and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial.
Topics: Administration, Topical; Adult; Aged; Anticarcinogenic Agents; Bexarotene; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Skin Neoplasms; Tetrahydronaphthalenes; Time Factors | 2003 |
6 other study(ies) available for bexarotene and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
Topics: Bexarotene; Brentuximab Vedotin; Canada; Cost-Benefit Analysis; Humans; Immunoconjugates; Lymphoma, T-Cell, Cutaneous; Methotrexate; Neoplasm Recurrence, Local; Physicians; Skin Neoplasms | 2023 |
Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed/refractory mycosis fungoides.
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Female; Humans; Male; Middle Aged; Mycosis Fungoides; Neoplasm Recurrence, Local; Retrospective Studies; Tetrahydronaphthalenes; Treatment Outcome | 2014 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |
Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Facial Neoplasms; Female; Humans; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Neoplasm Recurrence, Local; Photopheresis; Prednisone; Salvage Therapy; Skin Neoplasms; Tetrahydronaphthalenes; Vincristine | 2009 |
Systemic progression following complete cutaneous remission under bexarotene treatment for tumor-stage mycosis fungoides.
Topics: Bexarotene; Biopsy, Needle; Combined Modality Therapy; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Mycosis Fungoides; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retreatment; Risk Assessment; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2009 |
Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene.
Topics: Anticarcinogenic Agents; Bexarotene; Female; Humans; Ki-1 Antigen; Lymphoma, Large-Cell, Anaplastic; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome | 2011 |